# Chai Peptide — Cognitive & Nootropic research peptides > Chai Peptide is a plain-English reading room for two Cognitive & Nootropic research peptides — DSIP and Semax — studied for calm, focus and sleep. Peer-reviewed citations, no products, no medical advice. A plain-English reading room for DSIP and Semax — one studied around sleep, one around focus — and an honest account of what the evidence for each actually shows. ## The short version Chai Peptide is a reading room, not a shop. It exists to explain, in plain language, what the published research actually says about two peptides people reach for when they want a **calmer mind, sharper focus, or better sleep**: DSIP and Semax. Think of them as opposite ends of the same daily clock. **DSIP** (Delta Sleep-Inducing Peptide) is named for a wind-down effect first observed in sleeping rabbits, and it is studied mostly around sleep and the body's stress response. **Semax** is the lead compound here — a small, synthetic peptide studied for decades in Russia around alertness, memory, and recovery after brain injury. Neither is an approved medicine in the United States. Semax is a registered prescription drug only in Russia and Ukraine; DSIP is not approved anywhere. Both are sold online as unregulated research chemicals. This site cites the actual studies, describes them at their real strength — including where the evidence is thin — and never tells anyone what dose to take. ## Calm, focus, and sleep: how these two peptides fit together The organizing idea on this desk is the daily rhythm a nervous system runs on: wind down toward sleep at night, wind up toward focus during the day. **DSIP sits at the sleep end.** In a 2024 mouse study, an engineered DSIP fusion peptide designed to cross the blood-brain barrier cut nightly wakefulness by roughly a third in animals given an insomnia-inducing drug [1] — but a widely cited 2006 review is blunt that DSIP's underlying sleep evidence is, in its words, "extremely poorly documented and still weak" [2]. Reading DSIP means holding both of those facts at once. **Semax sits at the focus end.** Rather than working like a stimulant, it nudges the brain's own growth-and-repair chemistry — proteins called BDNF and NGF — upward in specific brain regions within hours of a dose in rodent studies [8][9]. That is a fundamentally different mechanism from anything that forces wakefulness; it behaves more like fertilizer for existing brain circuitry than a switch. Because these two peptides anchor opposite ends of the same daily arc, and because people researching one tend to ask about the other, this site pairs them rather than treating them as unrelated compounds. Read either [DSIP](/dsip) or [Semax](/semax) on its own, or [compare them directly](/compare). ## What are research peptides? Peptides are short chains of amino acids — the same building blocks that make up proteins, just far smaller. DSIP is a naturally occurring nonapeptide (nine amino acids) first isolated from animal blood; Semax is a synthetic heptapeptide (seven amino acids) engineered by researchers to resemble a fragment of a natural hormone. Both act on the brain and nervous system, which is why they get grouped as "nootropic" or "neuroactive" peptides even though their mechanisms have little in common. Neither compound is an FDA-approved medicine, and neither is manufactured to pharmaceutical standards when sold as a "research chemical" online. That label matters: research-grade material has no guaranteed purity, sterility, or accurate concentration, and the studies described on this site were almost all conducted in animals, in a handful of small older human trials, or in test tubes — not on the product a person could buy today. Whenever this site reports a number from a study, it reports it exactly as the study measured it, in the species that was studied, never as a recommendation for a person. ## How this desk reads DSIP and Semax The two compounds on this desk come with very different kinds of evidence, and we try to say so plainly rather than smoothing them into equally confident claims. DSIP's core problem is not a lack of studies — it is that the studies disagree with each other, and after four decades nobody has identified the receptor, gene, or precursor that would explain how it works [2]. Semax's core problem is different: it has a much more coherent, mechanistically grounded body of work, but almost all of it comes from a small cluster of Russian research groups and rodent models, with very little independent replication in Western human trials. Where community reports exist, they are labeled clearly as anecdotal and never treated as evidence of efficacy or safety. Where the clinical or preclinical literature disagrees with popular belief about a compound, that disagreement is reported, not buried. --- Chai Peptide steeps peer-reviewed findings into plain language — no prescriptions, no products, just a clearer read of what has actually been studied.